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Abstract 
Supramolecular gels have recently emerged as promising biomaterials for the delivery of a wide range 
of bioactive molecules, from small hydrophobic drugs to large biomolecules such as proteins. Although 
it has been demonstrated that each encapsulated molecule has a different release profile from the 
hydrogel, so far diffusion and steric impediment have been identified as the only mechanisms for the 
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release of molecules from supramolecular gels. Erosion of a supramolecular gel has not yet been 
reported to contribute to the release profiles of encapsulated molecules. Here, we use a novel 
nucleoside-based supramolecular gel as a drug delivery system for proteins with different properties 
and a hydrophobic dye and describe for the first time how these materials interact, encapsulate and 
eventually release bioactive molecules through an erosion-based process. Through fluorescence 
microscopy and spectroscopy as well as Small Angle X-ray scattering, we show that the encapsulated 
molecules directly interact with the hydrogel fibres - rather than being physically entrapped in the gel 
network. The ability of these materials to protect proteins against enzymatic degradation is also 
demonstrated here for the first time. In addition, the released proteins were proven to be functional 
in vitro. Real-time fluorescence microscopy together with macroscopic release studies confirm that 
erosion is the key release mechanism. In vivo, the gel completely degrades after two weeks and no 
signs of inflammation are detected, demonstrating its in vivo safety. By establishing the contribution 
of erosion as a key driving force behind the release of bioactive molecules from supramolecular gels, 
this work provides mechanistic insight into the way molecules with different properties are 
encapsulated and released from a nucleoside-based supramolecular gel and sets the basis for the 
design of more tailored supramolecular gels for drug delivery applications.  
Key words   
Biomaterials, gel erosion, self-assembled materials, drug delivery, mechanism, proteins, small 
molecules, biocompatibility 
 
1. Introduction 
Hydrogels for biomedical applications such as tissue engineering and drug delivery are widely reported 
[1-3]. Hydrogels are traditionally divided into polymeric gels that consist of covalently cross-linked 
polymer networks and supramolecular gels, consisting of fibrillar networks formed through non-
covalent interactions [4]. Recently, supramolecular gels have attracted significant attention in drug 
delivery, especially in the delivery of biologics [5], where they have demonstrated numerous 
advantages over polymer based gels  including the fine tuning of their properties through different 
stimuli; self-healing; and, mostly involve mild conditions of gelation that do not compromise the 
stability of sensitive biopharmaceutical molecules such as proteins and nucleic acids during 
encapsulation [6-8]. On the other hand, the crosslinking of polymeric gels can involve harsh conditions 
of gelation such as UV light or low pH to initiate cross-linking or the use of solvents which has been  
proven detrimental for the functionality of biopharmaceuticals [9].  
Bioinspired gelators based on peptides[10] and nucleic acids are popular candidates for drug delivery 
systems[7, 11] because of their inherent biocompatibility due to their high water content and their 
self-healing properties [7]. For example Puramatrix®, a self-assembling acetyl-(Arg-Ala-Asp-Ala)₄-
CONH₂ peptide that forms a stable hydrogel after increasing the pH and the ionic strength, has been 
employed for a broad range of clinical applications and has successfully delivered several biologically-
active agents such as proteins (growth factors, cytokines, insulin or antibodies) and siRNA in preclinical 
in vivo studies [12-14]. Peptide-based gels, however, have been shown to be susceptible to proteolytic 
enzymatic degradation and chemical modifications are necessary to improve their biostability [15-17]. 
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Nucleoside-based gelators are proposed as a novel alternative modality that would be stable against 
proteolytic enzymes.  
Nucleoside-based gels have recently been introduced as injectable delivery systems that can reform 
in situ after injection at the site of action [18], delivering  different classes of molecules from small 
therapeutic molecules to macromolecules such as proteins and nucleic acids [19, 20]. For example, a 
guanosine-5′-hydrazide gel was able to encapsulate various pharmacologically active molecules such 
as  acyclovir, vitamin C and vancomycin[21], whereas a 5’-deoxy-5’-iodoguanosine gel was reported 
to incorporate antivirals [22]. Additionally, Kaplan et al. demonstrated that a thymidine-based 
mechanoresponsive hydrogel can be used for the delivery of antibodies [19]. A urea based-
bolamphiphile was found to avoid the foreign body reaction after in vivo injection, demonstrating the 
ability of these types of gels to be immunocompatible [18]. Ramin et al. reported  the sustained release 
of a small hydrophobic fluorescent dye and a fluorescently labelled protein through a nucleotide lipid 
containing thymidine and 1,2 –dipalmitoyl-sn-glycerol phosphate paired with different cations with 
no toxicity in vivo [20] . Additionally this hydrogel was shown to protect the integrity of the model 
protein in vivo for a period of a few days compared to the non-formulated protein, successfully 
demonstrating the potential of these materials. Interestingly, the authors reported that, despite their 
size, the small hydrophobic molecule was released more slowly compared to the larger, more 
hydrophilic protein, raising questions over the influence that the properties of the molecules of 
interest can have on the encapsulation mechanism and the release behaviour of the final formulation.  
 
Proteins are complex macromolecules with a diversity of chemical groups exposed on the surface or 
buried in their core depending on the nature of the surrounding environment. Two major properties 
that define their behavior in solution are their molecular weight (MW) and charge. Until now, protein 
release from supramolecular gels has been demonstrated to be strongly influenced by the proteins' 
MW and charge [23-25].  Mechanisms that have been identified to control the release of proteins from 
supramolecular gels including diffusion, electrostatic interactions and steric impediment through the 
hydrophilic pores created by the 3D nanofiber scaffold of the hydrogel [23-25]. In addition, our work 
[26] and that of others [27-29] has demonstrated that proteins encapsulated in supramolecular gels 
can be immobilised by the naonofiber scaffold through interactions with the hydrophobic core of the 
gel nanofibers. Hence, we postulate that this interaction of the protein with the gel nanofiber could 
have a significant effect on the protein release profile and, if this is the case, that the mechanism of 
protein release will be dominated by an erosion process. To date erosion based mechanisms have only 
been demonstrated for polymer hydrogels but not for supramolecular gels [9, 30, 31].      
Herein, we use the well characterised, self-healing nucleoside-based hydrogelator N4-octanoyl-2’-
deoxycytidine[32, 33] developed in our group (SI, Fig. S1), to encapsulate a broad range of molecules 
(a small hydrophobic molecule and several proteins) and characterize its performance as a drug 
delivery system in vivo and in vitro. This nucleoside-based gelator was previously shown to 
encapsulate a hydrophobic dye (model molecule for hydrophobic drugs) selectively into the 
hydrophobic core of the fibers [33]. Although others in the field have used nucleoside gelators for 
protein delivery [19, 20], the novelty of this work is that we mechanistically investigate how proteins 
with different properties associate with the gel nanofibers and, for the first time for a supramolecular 
gel, we report the detailed mechanism of encapsulation and release of therapeutically relevant 
molecules and erosion of the gel. After release, we demonstrate that functional proteins (lysozyme 
and insulin) retain their biological activity in vitro. Furthermore, the ability of the gel to improve the 
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stability of a model protein in the presence of proteolytic enzymes compared to the protein alone is 
demonstrated for the first time. Finally, the release of a small hydrophobic dye and a fluorescently 
labeled protein as well as their effect on the gel degradation profile are studied in vitro and in vivo.  
2. Results and Discussion 
2.1 Encapsulation of proteins in hydrogels 
In order to investigate the potential of the hydrogel to act as a drug delivery system for the controlled 
release of different proteins we incorporated four model proteins into the gel (SI, Fig. S2). Bovine 
Serum Albumin (BSA), β-lactoglobulin (β-lact) and insulin (ins) are negatively charged at physiological 
pH (PBS, pH 7.4) but possess different MWs whereas β-lactoglobulin and lysozyme (lys) have 
similar/comparable MWs but are negatively and positively charged, respectively, at physiological pH. 
Stable gels were obtained after encapsulation of all proteins, (SI, Fig. S3).  
This hydrogelator has been previously reported to be self-healing [32]. This is an important condition 
for the syringeability of the gel and its ability to reform in situ. Rheology measurements have been 
extensively used in the literature to simulate the shear stress during syringing [18, 24, 32]. Here, we 
perform time dependent rheology measurements (SI, Fig. S4) which confirm that the presence of the 
protein is not preventing the ability of the gel to self-heal.  
After establishing that a self-healing supramolecular gel can be formed with the N4-octanoyl-2’-
deoxycytidine gelator in the presence of proteins with different MWs and charge we investigated how 
the proteins were entrapped within the gel. Previous literature has demonstrated that peptide based 
supramolecular hydrogels can immobilise proteins through the interaction of the protein with the 
hydrophobic core of the nanofiber [27-29] but physical entrapment of the proteins in the hydrophilic 
cavities of the nanofibrous gel network may also be possible in our system.  
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Fig. 1: Fluorescence images of gels (concentration 0.5% w/v)  (left column ) and solutions (right column) containing (30 μM)  
protein  labelled with fluorescamine in PBS for 4 h at 37 °C; BSA, -lactoglobulin, lysozyme, insulin and gel alone (from top 
to bottom). The 405 nm laser was set to 0.8%, emission detected at: 490 – 624 nm, channel colour (LUT) was set to green. 
2.2.1 Protein-gel fibre association  
In order to investigate the location of the proteins in the gel and elucidate the interaction between 
nanofibers and proteins we used fluorescence microscopy to image fluorescamine labelled proteins. 
Fluorescamine is a well-established dye in protein quantification as it reacts with primary amines and 
forms fluorescent complexes, consequently it is selective for the proteins and not the gelator[34]. In 
the presence of the labelled proteins, fibrous structures can be observed (Fig. 1) that are similar in 
appearance to the fibrous structure of the gel that was reported before [32]. As the gel fibers alone 
are not fluorescent (at λex=405 nm), the observation of fibres can be assumed to be caused by the 
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association of fluorescent proteins with the gel fibre network. The dispersed points giving strong 
fluorescence signals across the fibre network are likely due to protein and/or dye associated with fibre 
bundles (crossover points) or dye/protein aggregates. Note that the size of the observed features does 
not correspond to their actual dimensions. The diameters of the fibers (254 nm) observed in  
fluorescence microscopy were considerably larger than expected (~13 nm) [33] which is attributed to 
instrumental limitations (Raleigh/Abbe criteria, signal to background and signal to noise (of the 
detector) ratio). 
2.2.2 Hydrophobic protein-gel fibre interactions  
The intrinsic fluorescence of both the proteins and the gel was used for further evaluation of the 
interaction of the protein with the fibers [35]. The protein’s intrinsic fluorescence is due to the 
presence of aromatic amino acids and a change in their surrounding environment can result in a 
change in the fluorescence intensity or emission maxima [35]. The gelator is non-fluorescent in 
solution but it fluoresces in the self-assembled state, as previously reported [33]. As presented in Fig. 
2, emission spectra were recorded for the gel after the encapsulation of the proteins, the gel and the 
proteins alone, after excitation at two wavelengths that have been widely used for the excitation of 
proteins, 275 nm for the general excitation of the three aromatic amino acids and 295 nm for the 
specific excitation of tryptophan (human insulin has no tryptophan, so no emission after excitation at 
295 nm is detected).  
  
Fig. 2: Fluorescence emission spectra for gels (at concentration 0.5% w/v) containing four different proteins (30 μΜ) and the 
gel alone in PBS (30 μM for all proteins in gel and solution, apart from insulin which is 3 μM to allow recording of samples of 
insulin in gel and solution with the same instrumental settings). In every graph, protein containing gel after excitation at 295 
nm (black solid), protein containing gel after excitation at 275 nm (green solid), protein in solution after at 295 nm (black 
bold), protein in solution after excitation at 275 nm (green bold), gel without protein after excitation at 295 nm (black 
dashed), gel without protein after excitation at 275 nm (green dashed). The two minor peaks between 400 nm and 450 nm 
on the spectra of the gels containing β-lactoglobulin and insulin have been identified as artefacts and are not related to the 
protein/gel intrinsic fluorescence. 
Compared to the spectra obtained from protein solutions, the fluorescence emission spectra of all 
four different proteins in the gels shift and fully overlap with the emission spectra of the gel without 
the proteins. This suggests that the protein’s intrinsic fluorescence is fully quenched due to their 
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association with the fibers and only the fluorescence of the gel is detected. This may be the result of 
a change in the environment of the aromatic amino acids in the protein structure and indicates that 
these aromatic amino acids are directly involved in the fiber-protein interactions.  
2.2.3 Small Angle X-ray Scattering studies     
To understand if the presence of the protein is affecting the structure of the fibres, we performed 
Small Angle X-Ray Scattering (SAXS) measurements of the gels with proteins, the proteins in solution 
and the gel alone to determine the gel fibre diameters (Fig. 3 and SI Fig. S6). SAXS has been previously 
used to investigate the structures of supramolecular gels [33, 36, 37] as well as the effect that 
molecules encapsulated in the fibre have on the fibre diameter [38]. The gel sample was fitted to a 
flexible cylinder model (as previously reported for similar systems) [38], revealing a fibre radius of 73.2 
Å, in good agreement with previously published data [33]. Since fluorescence microscopy images 
showed that the proteins locate themselves on the fibres yielding cylindrical geometries, the SAXS 
patterns obtained from protein containing gels were fitted to a flexible cylinder model in the same 
manner as the gel sample that did not contain proteins, yielding fibre radii of 91.2 ± 0.4 Å (BSA), 66.6 
± 0.4 Å  (β-lactoglobulin), 71.1 ± 0.9 Å  (lysozyme) and 67.6±0.9 Å (insulin). The fitting parameters are 
presented in SI, Table S1. All fibre diameters cluster around the same range of values except that for 
the BSA containing gel. This indicates that there is an ordered association of BSA with the fibre. The 
other proteins likely associate with the fibres by arranging themselves in a non-ordered, amorphous 
structure surrounding the main gel fibre which would not be detectable by X-ray scattering. Together, 
the fluorescence microscopy and spectroscopy as well as the SAXS data (for BSA) provide 
complementary evidence that the proteins are not loosely entrapped in hydrophilic cavities between 
the gel fibres. Instead, the proteins engage in interactions with the gel fibres that result in a close 
association and co-localisation of the proteins and the fibres. 
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Fig. 3: Fibre radii determined from SAXS data obtained from gels (at concentration 0.5% w/v) with the four different proteins 
(30 μΜ) and the gel alone in PBS at room temperature. The data points represent the average fitted values of the radii and 
standard errors of the fitted values are also presented as error bars. 
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2.3 Prevention of protein enzymatic degradation  
As one of the main drivers of protein encapsulation in gels is to protect them from enzymatic 
degradation, we subsequently evaluated whether the protein-gel association could be beneficial in 
preventing enzymatic degradation of the proteins. We have previously shown that the nucleoside gels 
used here are able to protect proteins from pH induced denaturation [26]. The ability of gels to provide 
protection against enzymatic degradation has been extensively suggested but never clearly 
demonstrated. Here, we exposed the BSA containing gels to two model proteolytic enzymes, α-
chymotrypsin [39] and pepsin [40]. These enzymes are encountered in the human body, are readily 
available and inexpensive. Bovine Serum Albumin was chosen as the model protein due to its relative 
high molecular weight that would allow for a clear demonstration of the protein breakdown into 
shorter protein fragments in SDS-PAGE separation.  
Samples of gels containing proteins (G) and samples of the protein in solution alone (P) were incubated 
for different time periods (1 h, 4 h and 1 day) in the presence of enzymes before analysing them using 
SDS-PAGE (Fig. 4). When the band that corresponds to BSA (highlighted in Fig 4) was compared 
between samples containing protein only and protein in the presence of the gel, it is evident that for 
both enzymes the band intensity and hence the amount of intact protein for the protein alone was 
notably lower than for the protein/gel sample at all time points. At the later time points, the band 
intensity faded for the protein in the gel as well. This indicates that even though BSA degrades in both 
samples, the degradation process is considerably slower in the gel containing system, supporting the 
supposition that the presence of the gel has a protective effect on enzymatic degradation. The 
eventual decrease in the total amount of protein in the gel sample could be attributed to enzymes 
slowly diffusing into the gel, BSA partially diffusing out of the gel, the gel slowly eroding or a 
combination of all three processes. 
 
Fig. 4: SDS-PAGE for BSA (30 μM) encapsulated in gels (G) and BSA alone (P) after incubation with two different enzymes; 
chymotrypsin and pepsin for 1 h, 4 h and 1 day. In 120 μL of gel (0.5% w/v) in different buffers (50 mM KH2PO4 (pH = 4.5)  for 
pepsin and PBS for chymotrypsin), 10 μL (5 mg/ml,  ≥1250 units/mg) of pepsin and 20 μL (2 mg/ml, ≥80 units/mg) of 
chymotrypsin were pipetted on top of the already formed gel and incubated at 37 °C. 
2.4 Protein release and gel erosion   
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The close association of the proteins with the gel fibres allows for two possibile mechanisms (or a 
combination of both) of protein release from the system; dissociation of the protein from the fibres 
and diffusion out of the gel or degradation of the gel structure where the breakdown of the fibre 
structure ultimately results in the liberation of the proteins. We therefore investigated the in vitro 
release of the same set of proteins (BSA, β-lact, ins and lys) from the gels. Gels without (Fig. 5A) and 
with the proteins (Fig. 5B) were brought in contact with PBS at 37 °C and samples of the supernatant 
were taken at different time points. The concentration of the proteins at each time point was 
determined using the colorimetric Bradford assay, measuring the absorbance at 595 nm[41] and the 
gelator concentration was quantified through its UV absorbance at 295 nm (Fig. 5A). 
Interestingly, the release profiles of all proteins followed the same trend, regardless of the different 
protein properties (Fig. 5B). Notably, the release profile also matched the profile of the physical 
degradation of the gel, suggesting that gel degradation may be a key release mechanism for proteins 
from this system. For polymeric gels both diffusion and erosion/degradation have been reported to 
regulate the release depending on the formulation [9]. For example, for Pluronic gels encapsulating 
the therapeutic proteins insulin[30] and IL-2[31], it was demonstrated that gel erosion underpins the 
release mechanism. To date, for supramolecular gels the protein release mechanisms have been 
identified as diffusion out of the gel, with contributions from electrostatic interactions and steric 
impediment [23-25] whereas gel erosion has not been reported so far. Especially for supramolecular 
peptide-based gels, it has been previously demonstrated that proteins with different properties 
mainly diffused through the gel and had different release profiles depending on their properties [24], 
whereas no data have been reported so far on the release mechanism of nucleoside-based gels. For 
this nucleoside-based gel, the correlation of the kinetics of the protein release and gel degradation 
profile as well as the independence of the release profile on the type of the encapsulated protein, 
strongly suggest that erosion is the main mechanism by which proteins leave the gel. Macroscopic 
images of the gel eroding over time are presented in SI, Fig. S7.  
In order to study the gel erosion on the nanoscale, we used Atomic Force Microscopy (AFM).  Gels not 
containing proteins were incubated in PBS at 37 °C and after 4 h incubation samples drawn from the 
supernatant were imaged with AFM at 37 °C in PBS. Individual fibers were captured floating in the 
supernatant (Fig. 5C) demonstrating that intact fibers leave the bulk gel during gel erosion in a 
biologically relevant environment. Complementary data using fluorescence imaging that shows gel 
erosion in the presence of labelled BSA will be discussed in a later section. 
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Fig. 5: Formation of stable, self-healing gels able to deliver different proteins in a sustained way. (A) Release profiles of gel 
alone (grey trace) and (B) Release profiles of different proteins from the gel; blue (BSA), β-lactoglobulin (red), lysozyme 
(green), insulin (yellow) and gel alone (dashed grey trace). 0.5 ml of protein containing (30 μM) gel (0.5% w/v) were incubated 
with 1 ml PBS at 37 °C. The protein concentration  was determined at certain time points using a Bradford assay at 595 nm 
[41]. The gelator concentration was determined at 295 nm. (C) AFM images of gel fibers (gel alone at concentration 0.5% 
w/v) on mica imaged in the release medium (PBS) after 4 h incubation at 37 °C. 0.5 ml of gel (0.5% w/v) were incubated with 
1 ml PBS at 37 °C. 
 
2.4.1 Investigating the released protein functionality 
J
urn
al 
Pre
-pr
oo
f
11 
 
After evaluating that the gel provides sustained release a critical question is whether the functionality 
of the protein is preserved after encapsulation within the gel. This has also been a controversial topic 
for the polymeric gels [9].  Firstly, the integrity of all released proteins was tested with SDS-PAGE 
separation. As presented in Fig. 6A, all four released proteins have the same molecular weight as the 
proteins that did not undergo gel encapsulation (represented by the same band on the SDS-PAGE). 
Furthermore, the protein functionality is highly dependent on its secondary structure [42]. While 
circular dichroism would be a typical choice to study the secondary structure of proteins, in this system 
the strong CD activity of the gelator precludes the use of CD for the protein characterisation [33]. 
Considering this, we included a therapeutic protein, insulin and an enzyme, lysozyme in our study and 
assessed their activity after encapsulation [43].  
2.4.1.1 Insulin functionality  
To assess the bioactivity of insulin after the release through the gel, we used a cell-based functional 
assay. The HepG2 cells originate from a human liver carcinoma (one main target organ of insulin) and 
express abundant levels of the insulin receptor. A luciferase vector was transfected under the 
promoter fragment of the HMG CoA enzyme that is responsive to insulin [44-46]. The cell response to 
different doses of released insulin and insulin in solution was measured through luciferase activity. In 
Fig. 6B, insulin released from the gel (red bars) is plotted against insulin in solution (green bars). No 
difference between the bioactivity of the natural insulin and the released insulin was observed and, 
importantly a clear dose-response was observed at ranges of concentration similar to those present 
in humans, both at fasting (normal range 2-25 μUI/ml taken as a reference the Mayo Clinic laboratory 
fasting values for the normal population[47]) and at post-prandial levels (approximately 30-230 
μIU/ml [48]). There was no action of the released insulin on the mutated promoter bearing four point-
mutations, where also there was no action of the natural insulin, indicating that the response was 
specific for the insulin receptor (SI, Fig. S8). 
2.4.1.2 Lysozyme functionality 
Lysozyme is an antimicrobial enzyme that selectively cleaves β-1,4-glycosidic bonds between N-
acetylmuramic acid and N-acetylglucosamine present in bacterial cell walls [49]. The functionality of 
lysozyme has been previously assessed using Micrococcus lisodeikticus lyophilised cell walls as a 
substrate [43]. The lytic activities of the released lysozyme after encapsulation in the gel and free 
lysozyme are presented in Fig. 6C. Both traces (green and red) follow the same trend and are both 
distinctly different from the control (black trace), demonstrating that released lysozyme has the 
similar activity as free lysozyme. Incubation of the cells with the gelator alone did not cause a change 
in absorbance, indicating that the gelator does not affect the integrity of the cell wall and that a change 
in absorbance in the gelator/protein sample is due to lysozyme released from the gel. Jo
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Fig. 6: SDS-PAGE of different proteins (30 μM) BSA, β-lactoglobulin (β-lact), lysozyme (lys), insulin (ins) after encapsulation in 
the gel (0.5% w/v). Data are presented in pairs (first column control protein and second released protein). Dose response 
curve for human insulin was measured through luciferase activity;[50] gel alone (black trace), insulin released from gel in the 
presence of gelator (red trace) and insulin alone (green trace) (N=3 with 6 replicate measurements each). Turbidimetric assay 
of lysozyme; absorbance at 460 nm of Micrococcus Lisodeikticus lyophilised cell walls in the presence of gel alone (black 
trace), released protein (red trace) in the presence of gel, lysozyme control (green trace),(N=3).  
 
2.5 Release of small molecules and proteins 
Upon demonstrating the ability of this hydrogel to sustain controlled release of functional proteins in 
vitro, we progressed to an assessment of the protein release in vivo using a fluorescently labelled 
protein (cyanine 5-BSA, Cy5-BSA). Our previous work has shown that a small hydrophobic dye can be 
encapsulated in the hydrophobic core of the fibers of this gelator [33]. Alongside the fluorescently 
labelled protein, we therefore also tested the release of a fluorescent dye (1,1'-dioctadecyl-3,3,3',3'-
tetramethylindocarbocyanine perchlorate, Dil) incorporated in the hydrophobic core of the nanofibers 
as a model for a small molecule hydrophobic drug molecule. The fluorescent probes were selected 
due to their good contrast in the In Vivo Imaging System (IVIS)® we employed. The purpose of these 
experiments is to investigate the release profiles of Cy5-BSA in vivo and the biocompatibility of the 
gel. Before moving to the in vivo experiments, we monitored the Cy5-BSA and Dil containing gels with 
fluorescence microscopy, investigating their release behaviour in vitro to help understand their in vivo 
behaviour.  
2.5.1 Fluorescently labelled protein and fluorescent dye release in vitro  
Real time fluorescence microscopy was used to follow the release of the encapsulated molecules from 
the gel in vitro. Gels containing either Dil or Cy5-BSA were prepared and incubated in PBS at 37 °C for 
48 h. Images were captured at t=0 min, 10 min, 24 h and 48 h and are presented Fig. 7. For t=0 min, 
the fluorescent molecules directly associate with the fibers in both samples. It is important to highlight 
again that the gel alone was not fluorescent and the fluorescence signal can be  exclusively associated 
with the presence of the encapsulated molecule (Cy5-BSA or Dil).  
At t=0 min, both samples show an extensive fluorescent network of fibers with dispersed points giving 
strong fluorescence signals, most likely due to protein and/or dye associated with fibre bundles 
(crossover points) or dye/protein aggregates (note that the size of the observed features does not 
correspond to their actual dimensions due to the method’s limitations). After 10 min, we focused on 
the gel-PBS interface, where fluorescent fibers and protein aggregates were observed to be present 
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on the outside of the bulk gel, suggesting that the protein aggregates were released from the gel (Fig. 
7, zoom in at 10 min). 
A similar observation was made with Dil encapsulated in the gel where fluorescent fibers as well as 
dye aggregates are found on the outside of the bulk gel. After 1 day, in both cases the bulk gel had 
been fully eroded leaving smaller gel fragments floating in the medium. In the case of Cy5-BSA, 
fluorescent structures of different sizes (<20 μm) and shapes were floating in the medium whereas in 
the case of Dil encapsulating gel, significantly larger gel fragments  were visible with diameters of more 
than 100 μm, suggesting that fibers are held together for longer in the latter. In the case of Dil 
encapsulating gel fragments, fibers were protruding out from the gel phase into the gel-medium 
interface, suggesting that interfacial erosion of the gel occurs through the loss of single fibers from 
the gel phase (SI, Fig. S9).  
This data corroborates the in vitro protein release data above (Fig. 5B) that showed that the release 
of different encapsulated proteins from the gel followed the degradation of the gel.  
In the case of the encapsulated hydrophobic dye (Dil), in vitro release data were impossible to acquire 
due to the high hydrophobicity of the dye that tended to interact strongly with the containers and not 
remain in solution. Even when different solvents were used to extract the dye, exact quantification 
was not possible. The use of an alternative dye was not an option at this stage as in contrast to other 
dyes Dil demonstrated selective binding into the hydrophobic cavity of the fibers and provided 
adequate contrast for the subsequent IVIS® study. Due to this, macroscopic images of the degradation 
of the gel encapsulating the dye and the gel alone are presented in Fig. S10, SI, over a course of 24 h. 
As the volume of the gel encapsulating Dil and the gel alone reduced in a similar manner over time, 
we assume that the release of the dye follows the gel erosion as well and the gel completely degrades 
macroscopically within 1 day. The in vitro release data (Fig 5B) are in good agreement with the 
fluorescence microscopy images that show gel breakdown within 24 h. The fluorescence microscopy 
images showed that the gel encapsulating the dye and the gel encapsulating the protein followed two 
different breakdown pathways; the first broke down into gel particles whereas the second into fibre 
bundles, suggesting that the forces holding the fibers together for the gel encapsulating the dye are 
stronger compared to the gel encapsulating the protein. 
2.5.2 Fluorescently labelled protein and fluorescent dye release in vivo   
To obtain a preliminary insight into the safety of the material in vivo and its potential as a drug delivery 
system, we performed IVIS® imaging following similar studies in the literature [20]. To date, a limited 
number of nucleoside-based gelators have been tested in vivo [18, 20]. In this work, we used a 
nucleoside-based gel encapsulating a small hydrophobic dye (Dil) or Cy5-BSA in order to evaluate the 
release of these model molecules from the gel in vivo.  
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Fig. 7: Fluorescence microscopy images of gels (0.5% w/v) encapsulating Cy5-BSA at a final concentration of 15 μM (left) and 
hydrophobic dye (Dil) at a final concentration of 8.3 μM (right) at after incubation with PBS at 37 ˚C at different time points 
(t=0 min, 10 min, 24 h, 48 h). The arrows indicate the gel-PBS interface. In each case a large area image (map) and a zoom in 
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image were recorded. For the Cy5 labelled protein, 647 nm laser was set to 4%, emission detected at 654 – 752 nm, channel 
colour (LUT) was set to magenta; for Dil, 561 nm laser was set to 0.1%, emission detected at 561 – 624nm. 
Hydrogels containing Cy5-BSA and Dil, Cy5-BSA in solution and gel alone were injected subcutaneously 
into mice. In Fig. 8A, IVIS® images of the mice are presented at different time points (0 hr, 1 h, 24 h 
and 2 weeks after subcutaneous injection) for gels encapsulating Cy5-BSA (top) and Dil (bottom). In 
both cases the fluorescence intensity faded out over time and was almost zero after two weeks (very 
low levels of fluorescence were detected probably due to association of the dye with tissue). No 
control group was injected with Dil in solution as Dil is highly hydrophobic and remains completely 
insoluble in PBS. Fluorescence data of the encapsulated molecules were extracted for quantification 
and are presented in Fig. 8B. In all cases there was an increase in the fluorescence intensity of the 
encapsulated molecules during the first 4 hours, probably due to the gel reformation after the shear 
stress applied during injection. Another explanation could be equilibration phenomena of the 
fluorescent probe in the lipophilic tissue environment that have been previously reported [51]. After 
this period, fluorescence intensity started to drop as expected. 
Fluorescence data of the gel containing Cy5-BSA and Cy5-BSA in solution (Fig. 8B) suggests that 
encapsulation in the gel increased retention of Cy5-BSA compared to Cy5-BSA in solution. In both 
cases, the mice of both groups were healthy when sacrificed after 2 weeks and there was no 
macroscopic trace of the gel in the tissue, indicating that the gel is biodegradable in vivo (Fig. 8D).  
2.6 Biocompatibility in vivo  
In order to investigate if the gel causes any inflammation, cross-sections of the tissue at the site of 
injection and surrounding the site of injection of the gel alone were stained with haematoxylin and 
eosin imaged as shown in Fig. 8D and Fig. S15. Tissue and cell morphology throughout the entire area 
of all samples appeared comparable to the control (Fig. S16). There was no evidence of the gel depot 
itself or of cellular or tissue damage from the gel in the samples. Areas of haemorrhage or excessive 
immune cell infiltration (including cells such as mononuclear leukocytes and polymorphonuclear cells) 
were not visualised within any of the tissues assessed. The basic histological investigations indicated 
no damage to the cells within the tissue where the gel had resided. These samples were measured 2 
weeks after injection, therefore, at this stage we can conclude that no chronic inflammation or tissue 
necrosis was observed, suggesting that the material does not cause any permanent damage to tissue. 
It is possible that an immune cell response could have been present in the days immediately following 
injection as is usual following injections of biomaterials [52-55].  
3. Conclusions 
Supramolecular gels have emerged as promising biomaterials for drug delivery. Here, we demonstrate 
that nucleoside-based supramolecular materials form stable, self-healing gels in the presence of 
incorporated proteins. We report for the first time that gel erosion plays a key part in the release 
mechanism of proteins from a supramolecular gel and provides indicative evidence that this erosion 
based release process is related to the non-covalent association of proteins to the gel fibres. 
Interestingly, the erosion-based release profile of the proteins is independent of the type of proteins 
used. Protection from enzymatic degradation was shown to be a major advantage of these materials 
for protein delivery. Additionally, after in vitro release, proteins (such as lysozyme and insulin) are 
shown to maintain their functionality. In vivo injection of the nucleoside based hydrogel resulted in 
Jo
urn
al 
Pre
-pr
o
f
16 
 
no toxicity over two weeks and no signs of inflammation were detected. This highlights the suitability 
of supramolecular hydrogels to act as protective matrices for protein delivery and suggests that they 
could be used to release proteins in a manner that is independent of the nature of the proteins.  
 
Fig. 8: In vivo data of gels encapsulating Dil and Cy5-BSA after subcutaneous injection in mice (N=3 for each group); (A) IVIS® 
images of the mice after injection of 300 μl of gel (0.5% w/v) encapsulating Cy5-BSA (15 μM, top row), Cy5-BSA in solution 
(15 μM) and gel encapsulating a hydrophobic dye, Dil (8 μM). Images are presented in the same colour scale 6.00 x 108 - 1.00 
x 1010 (ρ/sec/cm2/sr) for the gel encapsulating Cy5-BSA and Cy5-BSA in solution and 3.50 x 108 - 7.00 x 109 (ρ/sec/cm2/sr) for 
all the images of the gel with Dil. (B) Normalised to maximum fluorescence intensity (fluorescence signal is measured in 
radiance over the same region of interest for all images) of gel encapsulating Cy5-BSA (solid trace) and Cy5-BSA in solution 
(dotted trace) and gel encapsulating Dil (dashed trace) (N=3). (C) Macroscopic image of tissue where control gel (without 
encapsulated molecule) was injected (D) Macroscopic image of tissue where control gel (without encapsulated molecule) 
was injected; after two weeks the animals were sacrificed and the gel had completely degraded. No control group was 
injected as Dil is highly hydrophobic and remains completely insoluble in PBS. The injection site is highlighted in red. (E) 
Photomicrograph showing normal cellular and tissue morphology. Haematoxylin and eosin were used to stain the tissue at 
and around the injection site 2 weeks after the injection of the control gel (without encapsulated molecule). Further 
photomicrographs and the control as given in the SI -Fig. S15 and Fig S16 respectively.     
 
4. Experimental methods 
4.1 Materials 
2′-Deoxycytidine (lot #SLBN6031, 99% [high-performance liquid chromatography (HPLC)]), pepsin 
from porcine gastric mucosa (#P7012, lyophilized powder, ≥2,500 units/mg protein (E1%/280)), 
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lysozyme from chicken egg white lyophilized powder (product # L6876, protein ≥90 %, ≥40,000 
units/mg protein), β-lactoglobulin B from bovine milk ( ≥90% (PAGE) product # L8005), Bovine Serum 
Albumin lyophilised powder, essentially fatty acid free and essentially globulin free, ≥99% ((agarose 
gel electrophoresis), product #A028) 1,1′-Dioctadecyl-3,3,3′,3′-tetramethylindocarbocyanine 
perchlorate 97% (product #468495) and fluorescamine [(product # 47614) BioReagent, suitable for 
fluorescence, ≥99.0% (UV)], C4129 α-Chymotrypsin from bovine pancreas, Type II, lyophilized powder, 
≥40 units/mg protein, (product # C4129), Micrococcus lisodeikticus lyophilised cells, Dulbecco’s 
Phosphate Buffered Saline Modified, (without calcium chloride and magnesium chloride, liquid, 
sterile-filtered, suitable for cell culture D8537) were purchased from Sigma Aldrich. Polyacrylamide 
gels 4–20% Mini-PROTEAN® TGX™ Precast Protein Gels, 12-well, 20 µl (#4561095) and Quick Start™ 
and Bradford 1x Dye Reagent (#5000205) were purchased from Bio-Rad. Cyanine5 NHS ester was 
purchased from Lumiprobe. Insuman Rapid 100 IU/ml solution for injection in a cartridge was 
purchased from Sanofi. SnakeSkin™ Dialysis Tubing was purchased from Thermofisher Scientific 
(Waltham, Massachusetts, United States), MWCO 3.5 kDa. For Fluorescence Microscopy Cellview cell 
culture slide (Item No.: 543079) were purchased from Greiner Bio-one. The gelator was synthesized 
according to previously published work. Analysis of the gelator was performed by NMR and liquid 
chromatography−mass spectrometry (LC−MS) (Supporting Information Figures S12 and S13), and 
purity was determined as 98% (LC−MS). [32] 
4.2 Gel preparation 
Certain amount of gelator was weighed out in 2 ml HPLC vial and dispersed with PBS in order to get a 
final concentration of 0.5% w/v. The vial was carefully sealed and the gelator was heated up to 100 ˚C 
till complete dissolution. The sealed vial was immersed in a water bath at 37 ˚C for 1 min before 
opening (allowing for water condensation) and certain amount of protein was pipetted in to achieve 
final protein concentration of 30 μM. For protein-gel association studies, stock solutions of proteins 
were prepared in PBS (Bovine Serum Albumin 27 mg/ml, Lysozyme 5.75 mg/ml, β-lactoglobulin, Insulin 
2 mg/ml) and 40 μl of protein stock solution was pipetted into 500 μl of gelator at 37 ˚C. For the Real 
Time Fluorescence Microscopy and the in vivo study 13.5 mg/ml stock solution of Cy5-BSA in PBS (the 
labelling protocol is described further below) were prepared and 48 μl of protein stock solution were 
pipetted into 552 μl gelator (37 ˚C), then a stock solution of 5 mg/ml Dil in ethanol was prepared and 
3 μl were pipetted into 600 μl of warm gelator. 
4.3 Release studies of proteins 
500 μL of gel containing protein in 2 ml HPLC vials were incubated with 1 ml PBS at 37 ˚C. The 
supernatant was removed at different time points (1, 2, 4, 6, 14  and 24 h) and replaced with fresh 
PBS. The protein concentration was determined using the Bradford colorimetric assay [41]. For 
lysozyme and β-lactoglobulin, 20 μl of supernatant at each time point was premixed with 200 μl 
Bradford reagent, for Bovine Serum Albumin 20 μl of supernatant were premixed with 200 l of 
Bradford reagent and for Insulin 100 μl of supernatant with 100 μl of Bradford reagent and absorbance 
at 595 nm was measured using a Tecan Spark 10 M/ 20 M plate reader. Ratios of supernatant: reagent 
were determined in order to provide with a linear calibration curve (Supplementary Information 
Figure S11). For each data point an average of 4 repeats is presented for the calibration curve and an 
average of 3 repeats for the protein release study.  
4.4 Gel degradation study 
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500 μL of gel in 2 ml HPLC vials were incubated with 1 ml PBS at 37 ˚C. The supernatant was removed 
at different time points ( the same as the protein release study; 1, 2, 4, 6, 14 and 24 h)  and replaced 
with fresh PBS. 40 μl of supernatant were premixed with 160 μl of methanol and the absorbance was 
measured at 295 nm in a quartz 96 well-plate using a Tecan Spark 10 M/ 20 M plate reader. For each 
data point an average of 4 repeats is presented for the calibration curve (Supplementary Information 
Figure S9) and an average of 3 repeats for the gel degradation study.  
4.5 Fluorescence spectroscopy 
600 μL of gel (with or without proteins prepared as explained above) were added to a 2 mm path 
length cuvette. Fluorescence spectra were recorded at a Cary Eclipse fluorescence 
spectrophotometer. The spectra were recorded with a scan rate of 30 nm/min, averaging time 1 s, 
and data interval 0.5 nm using different emission and excitation slits; for BSA (excitation slit 2.5 nm 
and emission slit 5 nm), β-lactoglobulin (excitation slit 5 nm and emission slit 5 nm), lysozyme 
(excitation slit 2.5 nm and emission slit 5 nm), insulin (excitation slit 5 nm and emission slit 5 nm). 
Samples were excited in all cases at 275 nm and 295 nm. Gels (concentration 5 mg/ml) with proteins 
(30 μM) were prepared and compared to protein solution in PBS (30 μM for all proteins apart from 
insulin that is 3 μM). 
4.6 Fluorescence microscopy 
15 μl of warm gelator solution (concentration 0.5% w/v) where the encapsulating molecule has 
already been added were pipetted in the well and the first image (t=0 min) was recorded. 400 μl of 
PBS were added and the well was transferred to 37 ˚C and images were recorder at t=10 min, 24 h, 48 
h. 
Gels were made and imaged in Cellview multiwell , glass bottom slides (0.17mm, category 1.5, product 
no: 543079). Fibers / gels and suspensions were visualized and scanned with the confocal unit of a 
Zeiss Elyra PS1 LSM780 microscope. Two different objectives were used, water immersion C-
Apochromat 63x/1.2 W Korr M27 for scanning the gels and solutions labelled with fluorescamine, and 
alpha-Plan-Apochromat 100x/1.46 oil objective for Dil and Cy5 labelled proteins and time laps 
experiments. Fluorescent dyes were detected with the following settings: for fluorescamine, 405 nm 
laser was set to 0.8%, emission detected at: 490 – 624 nm, channel colour (LUT) was set to green; for 
Cy5 labelled proteins, 647 nm laser was set to 4%, emission detected at 654 – 752 nm, channel colour 
(LUT) was set to magenta; for Dil, 561 nm laser was set to 0.1%, emission detected at 561 – 624 nm. 
To reduce noise, and reveal more details, for all the scans line averaging of 2, and slow scan of 6.3 µs 
dwell time was applied during scanning. Images and videos were exported using Zeiss Zen 2012 SP5, 
histogram values (display of the image brightness) was set to the same for the samples belonging to 
the same experiment.  
 
4.7 Protein Labelling 
0.4 mg Cyanine5 NHS ester were dissolved in 200 μl DMSO and 6 mg Bovine Serum Albumin were 
dissolved in 1800 μl NaHCO3 0.1 M (pH 8.3). The reaction was left under stirring overnight and the 
mixture was left to dialyse for 7 days using a 3.5 kDa dialysis tubing. After dialysis, the labelled protein 
was analysed by size exclusion chromatography (SEC) using a TSK gel G3000SWXL (300 × 7.8 mm) 
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column (TOSOH, Tokyo, Japan), running on a HPLC system. The protein was isocratically eluted in DPBS 
at a flow rate of 1 mL min-1. Fluorescence was recorded at λem = 666 nm, with excitation fixed at λex = 
644 nm. The chromatogram is presented in Figure S14. 
4.8 Enzymatic degradation study 
120 μL of warm gelator solution (0.5% w/v) in different buffers [50 mM KH2PO4 (pH = 4.5)  for pepsin 
and PBS for chymotrypsin] were pipetted into 1.5 ml plastic Eppendorf tubes and Bovine Serum 
Albumin (in PBS) was added, as described earlier, to achieve a final concentrations of 30 μM. 10 μL (5 
mg/ml) of pepsin and 20 μl (2 mg/ml) were pipetted on top of the already formed gel and incubated 
for 1 h, 4 h and 24 h at 37 ˚ C. Enzyme concentrations were selected in order to allow us to qualitatively 
assess the prevention of protein degradation, in a time course of 24 h.  At the previously mentioned 
time points, the enzymes were quenched after the addition of 80 μl SDS-PAGE Reducing Sample Buffer 
(RSB), plus 10 μl of HCl 1 M in the case of chymotrypsin, and the samples were denatured by heating 
at 100 ˚C for 5 min prior to gel loading. 10 μL of sample were pipetted into a 4–20% Mini-
PROTEAN® TGX™ Precast Protein Gel which was run in a standard running buffer (25 mM Tris, 192 mM 
glycine, 0.1% SDS). Gels were incubated in InstantBlue® (Expedeon, UK).  RSB contained 75 mM Tris–
HCl, pH 6.8, 10% glycerol, 2% SDS, 0.05% bromophenol blue, 2.5% β-mercaptoethanol.  
4.9 Samples for Small Angle X-ray scattering (SAXS)  
Samples for Small Angle X-ray scattering (SAXS) were prepared in 1.5 mm borosilicate glass capillaries 
(Capillary Tube Supplies Ltd) and sealed with a UV-curable adhesive (Norland Optical Adhesive). SAXS 
measurements were taken on a SAXSLab Ganesha 300XL instrument using a CuKα source (1.54 Å) and 
a Pilatus 300K detector. Data collection was performed over a Q range of 0.007-0.25 Å-1, with an 
exposure time of 7200 seconds per sample. A correction for tube thickness and curvature was applied 
during measurement, and a capillary of buffer was run in order to perform background subtraction. 
The data were fitted using the SasView 4.1 software package. 
4.10 Atomic Force Microscopy 
Gel solutions were prepared as previously described for the gel degradation study (see ‘Gel 
degradation study’ section). The supernatant after 4 h incubation was extracted and 40 μl were 
pippeted onto mica. Mica was transferred on preheated at 37 °C AFM stage. Adequate amount 
(approximately 50 μl) of PBS were added to immerse fully the AFM tip in liquid. Imaging was 
performed under Peak Force mode using the Bruker FastScan Dimension with ScanAnalyst AFM. 
4.11 Lysozyme functionality assay 
A turbidimetric enzymatic assay was performed by measuring the decrease in optical density of an 
aqueous suspension of Micrococcus lysodeikticus lyophilised cells, a natural substrate for lysozyme, 
in PBS. Gel with lysozyme was prepared as described before and 0.5 ml of gel was incubated with 1 ml 
of PBS at 37 °C for 24 h until gel erosion. The final concentration of lysozyme in the dispersion 
produced was 37 µg/mL. PBS (20 mL) solution was added to 10 mg of lyophilised cells. 300 µL of this 
substrate suspension were added to 150 µL of solution and the decrease in optical density at λ = 460 
nm was measured as a function of time. Free gelator and free lysozyme were used as controls at the 
same concentration as in the samples after incubation at the same conditions as lysozyme in the gel. 
All kinetic experiments were carried out in triplicate. 
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4.12 Evaluation of the insulin bioactivity in human cells 
The HepG2 cell line was obtained from ECACC (UK, distributed by SIGMA) and cultured in growth 
medium: EMEM (1 g glucose/L, SIGMA, UK) supplemented with 10 % FBS (GIBCO, Thermo South 
America), 1% Non-essential amino acids (GIBCO, Thermo Grand Island USA), 2 mM L-Glutamine 
(SIGMA Brazil), 1% Penicillin-Streptomycin (SIGMA Israel). HepG2 originated from a human liver 
carcinoma, a bona-fide insulin target organ, and are enriched in Insulin Receptor expression 
(https://www.proteinatlas.org/ENSG00000171105-INSR/cell). Cells were passaged once per week by 
trypsinization (10x Trypsin solution, SIGMA USA) for 5 minutes and passage through an 18 gauge 
needle to obtain a single cell suspension. They were used between passages 3 and 20.  
For transfection, Viafect (Promega, Madison USA), and Turbofect (Thermo, Lithuania) were compared 
by measuring the efficiency of transfection of a commercial plasmid preparation of pMAXGFP (Lonza, 
Köhln Germany) following the standard recommended protocols. Efficiency was calculated measuring 
the number of GFP fluorescent cells respect to the total number of cells stained with Hoescht 33258 
(SIGMA Israel). Apoptosis measured as condensed Hoescht+ cells was also measured and discarded 
for efficiency. Since Viafect obtained a >95% efficiency while Turbofect approached 65%, all 
subsequent experiments were performed using Viafect. 
MW48 plates (Costar, Thermo NY USA) were previously coated with 100 μg/ml Type I collagen solution 
in PBS (stock solution: 4 mg/ml, SIGMA St Louis MO USA) and washed three times with PBS (SIGMA St 
Louis MO USA). For each assay, 24000 HepG2 cells/well were seeded on these wells in growth 
medium, and allowed to grow for one full day. Next day, a transfection mix of DNA plasmid (85 ng of 
promoter+35 ng empty RSV plasmid/well), Viafect transfection reagent (1.5 µL/well) and EMEM (23.5 
µL/well) was prepared for all wells combined and incubated for 20 min. The plasmids used were: 
pSynSRE-T-luc (Addgene, Cambridge USA) containing the −324 to −225 bp fragment of the hamster 
HMG-CoA synthase promoter containing the SRE elements upstream of the minimal HMG-CoA 
synthase TATA box (−28 to +39) pSynSRE-Mut-T-luc bearing four point mutations in that promoter SRE 
elements[44, 45]. It has been previously shown that Insulin regulates HMG-CoA synthase expression 
through those SRE sites in human cells, and its action abolished in the mutated promoter[46] . 
Meanwhile, cell medium was replaced by growth medium plus 2 mM metformin (SIGMA, Steinheim 
Germany). Metformin helps to reduce the basal luciferase expression while the cells were under 
transfection. Subsequently, 25 µL of the transfection mix was pipetted per well and incubated during 
6 hours. After three washes with warm PBS were performed and changed to deprived medium (as 
growth medium but with only 0.5% FBS) including the insulin/vehicle to test (5-200 μIU/ml or 
equivalent vehicle volume). Each condition was tested in six-eight replicates. After 20 hr, wells were 
washed three times with PBS followed by addition of 40 µL PassiveLysis Buffer/well (Promega, 
Madison USA) for 20 min. Lysates were collected and frozen at -20 °C. Luciferase activity was assayed 
as described[56] using 15 μL of lysate in a Mithras microplate reader (LB940, Berthold, Bad Wildbad 
Germany). Experiments were repeated three times. 
Statistics and figures were performed with GraphPad 7 by applying first a Kolmogorov-Smirnov 
normality test and, being normally distributed, following by an unpaired t-test to assess significance. 
Insulin –Vehicle concentrations were plotted in parallel graphics comparing the normal SynSRE-T-luc 
and the mutated SynSRE-Mut-T-luc promoter (SI, Figure S6).  
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4.13 Rheology studies 
Rheology was carried out using an Anton Paar MCR302 Modular Compact Rheometer. A four bladed 
vane geometry was used with a diameter of 8.5 mm and length 8.5 mm in a cup with a diameter of 
14.5 mm. The solution of gelator was prepared in 7 mL aluminium cups to a final sample volume of 2 
mL, as per the method described above. Once the gel was prepared, the sample vial was mounted in 
the lower plate (cup) of the rheometer; the vane (attached to the upper part) was lowered into place, 
at a depth of 2 mm. This arrangement gave a total sample depth of approximately 16 mm in the 14.5 
mm diameter cup which allowed positioning of the vane in the centre of the sample. All rheological 
measurements were carried out in 7 mL aluminium vials to allow for heating at 37 ˚C of the sample 
prior to measurement. Time dependant recovery measurements were carried out by alternating the 
strain between 5% and 500%; conditions that could guarantee a stable gel at the lower strain and 
complete deformation at the higher strain. The strains were applied in 20 min (0.2%) and 30 sec 
(500%), followed by 30 min (0.2%) cycles. The frequency (5 rad/sec ) and temperature (37 ˚C) were 
kept constant throughout. 
4.14 In vivo study 
This study was conducted under the Animals (Scientific Procedures) Act 1986 UK Home Office Licence 
number PPL P435A9CF8, 19b and given ethical approval by the University of Nottingham AWERB. NCRI 
guidelines for the welfare and use of animals in cancer research, LASA good practice guidelines and 
FELASA working group on pain and distress guidelines were followed. ARRIVE Guidelines were 
followed in the reporting of the animal studies. 12 female CD-1 NuNu mice (12 weeks old) were 
obtained from Charles River (UK). Mice were maintained in IVCs (Tecniplast UK) within a barriered unit 
illuminated by fluorescent lights set to give a 12 h light-dark cycle (on 07.00, off 19.00), as 
recommended in the United Kingdom Home Office Animals (Scientific Procedures) Act 1986. The room 
was air-conditioned by a system designed to maintain an air temperature range of 21 ± 2 °C and a 
humidity of 55% + 10%. Mice were housed in social groups during the procedure with irradiated 
bedding and provided with autoclaved nesting materials and environmental enrichment. Daily 
monitoring of general health and well-being and weights was undertaken.  
After injections of the different formulations, fluorescence signal was measured at 0 hr, 1 h, 2 h, 4 h, 
24 h and 72 h followed by weekly imaging through IVIS Spectrum. The gels were prepared with a 
concentration 5 mg/ml of gelator, 0.025 mg/Ml Dil or 1 mg/mL Cy5-BSA. The gel containing Dil 
contained 0.5% v/v ethanol in order to solubilise the hydrophobic dye. 4 different groups of mice were 
used: (1) gels containing Dil, (2) gels containing Cy5-BSA, (3) gel alone, and (4) Cy5-BSA in solution. 
For the data processing the Living Image Software was used. Rectangular regions of interest (ROI) were 
drawn including the area occupied by the gel at t= 0 h. The same ROIs were used for the other time 
points. Fluorescence intensity values were extracted in radiance (ρ/sec/cm2/sr) and presented in the 
same colour scale.  
4.15 Inflammation markers at the site of injection 
Skin was excised from around the injection site including the area in which the gel had resided. All 
samples (samples with gel, N=3 and a control with no gel injected) were embedded in optimal cutting 
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temperature (OCT) compound using liquid nitrogen cooled isopentane. Serial sections 7 µm thick were 
cut from each block throughout the entire tissue on a crystat (Leica, Germany) and mounted on 
polysilinated microscope glass slides (Menzel Gläser Polysine®; Thermo-Scientific, Germany). 
Following embedding and sectioning, tissue sections were fixed in 4% paraformaldehyde for 5 min and 
stained using haematoxylin and eosin (H&E). H&E staining was achieved by immersing samples for 2.5 
min in haematoxylin, 15 s in 1% acetic industrial methylated spirits, 15 s in ammoniated water and 4 
min in eosin. Following staining were dehydrated through an ethanol series (50, 70, 90, 95 and 100% 
ethanol for 5 min each followed by 2X xylene immersions) and glass coverslips were mounted using 
DPX. Following staining, tissue and cell morphology was analysed throughout the tissue samples. The 
observer was blinded to the sample identification to avoid subconscious bias. Images were captured 
using a Leica CTR500 microscope (Leica Microsystems, Germany) with bright field light. For each 
sample several sections 200 µm apart were analysed at 5X, 10X, 20X, 40X and 60X magnifications and 
photomicrographs captured. 
 
Acknowledgements 
This work was supported by the EPSRC [EP/L01646X] via the CDT in Advanced Therapeutics and 
Nanomedicine. The authors would like to acknowledge the SLIM facility, University of Nottingham, 
funded by the BBSRC (grant number BB/L013827/1). The Ganesha X-ray scattering apparatus used for 
this research was purchased under EPSRC Grant `Atoms to Applications' Grant [EP/K035746/1]. This 
work benefited from SasView software, originally developed by the DANSE project under NSF award 
DMR-0520547. SasView also contains code developed with funding from the EU Horizon 2020 
programme under the SINE2020 [654000]. The authors would like to thank Alison Ritchie for her 
contribution in the in vivo experiment. 
 
 
References 
  
1. Hoffman, A.S., Hydrogels for biomedical applications. Advanced Drug Delivery Reviews, 
2012. 64: p. 18-23. 
2. Gupta, P., K. Vermani, and S. Garg, Hydrogels: from controlled release to pH-responsive drug 
delivery. Drug discovery today, 2002. 7(10): p. 569-579. 
3. Qiu, Y. and K. Park, Environment-sensitive hydrogels for drug delivery. Advanced drug 
delivery reviews, 2001. 53(3): p. 321-339. 
4. Flory, P., Introductory lecture. Faraday Discussions of the Chemical Society, 1974. 57: p. 7-18. 
5. Li, Y., F. Wang, and H. Cui, Peptide‐based supramolecular hydrogels for delivery of biologics. 
Bioengineering & Translational Medicine, 2016. 1(3): p. 306-322. 
6. Christoff-Tempesta, T., A.J. Lew, and J.H. Ortony, Beyond Covalent Crosslinks: Applications of 
Supramolecular Gels. Gels, 2018. 4(2): p. 40. 
7. Skilling, K.J., et al., Insights into low molecular mass organic gelators: a focus on drug 
delivery and tissue engineering applications. Soft Matter, 2014. 10(2): p. 237-256. 
8. Cui, H., M.J. Webber, and S.I. Stupp, Self‐assembly of peptide amphiphiles: From molecules 
to nanostructures to biomaterials. Peptide Science, 2010. 94(1): p. 1-18. 
9. Vermonden, T., R. Censi, and W.E. Hennink, Hydrogels for protein delivery. Chemical 
Reviews, 2012. 112(5): p. 2853-2888. 
10. Mart, R.J., et al., Peptide-based stimuli-responsive biomaterials. Soft Matter, 2006. 2(10): p. 
822-835. 
J
u n
l P
re-
p o
of
23 
 
11. Peters, G.M. and J.T. Davis, Supramolecular gels made from nucleobase, nucleoside and 
nucleotide analogs. Chemical Society Reviews, 2016. 45(11): p. 3188-3206. 
12. Tokunou, T., et al., Engineering insulin-like growth factor-1 for local delivery. The FASEB 
Journal, 2008. 22(6): p. 1886-1893. 
13. Guo, H., et al., Sustained delivery of VEGF from designer self-assembling peptides improves 
cardiac function after myocardial infarction. Biochemical and biophysical research 
communications, 2012. 424(1): p. 105-111. 
14. Nishimura, A., et al., Controlled release of insulin from self-assembling nanofiber hydrogel, 
PuraMatrix™: application for the subcutaneous injection in rats. European Journal of 
Pharmaceutical Sciences, 2012. 45(1-2): p. 1-7. 
15. Liang, G., et al., Supramolecular hydrogel of a D-amino acid dipeptide for controlled drug 
release in vivo. Langmuir, 2009. 25(15): p. 8419-8422. 
16. Li, X., et al., Introducing D-amino acid or simple glycoside into small peptides to enable 
supramolecular hydrogelators to resist proteolysis. Langmuir, 2012. 28(37): p. 13512-13517. 
17. Li, X., et al., Supramolecular hydrogels formed by the conjugates of nucleobases, Arg-Gly-Asp 
(RGD) peptides, and glucosamine. Soft Matter, 2012. 8(28): p. 7402-7407. 
18. Ramin, M.A., et al., Low molecular weight hydrogels derived from urea based-
bolaamphiphiles as new injectable biomaterials. Biomaterials, 2017. 145: p. 72-80. 
19. Kaplan, J., P. Barthélémy, and M. Grinstaff, Self-assembled nanofiber hydrogels for 
mechanoresponsive therapeutic anti-TNFα antibody delivery. Chemical Communications, 
2016. 52(34): p. 5860-5863. 
20. Ramin, M.A., et al., Cation tuning of supramolecular gel properties: a new paradigm for 
sustained drug delivery. Advanced Materials, 2017. 29(13): p. 1605227. 
21. Sreenivasachary, N. and J.M. Lehn, Structural Selection in G‐Quartet‐Based Hydrogels and 
Controlled Release of Bioactive Molecules. Chemistry–An Asian Journal, 2008. 3(1): p. 134-
139. 
22. Plank, T.N. and J.T. Davis, AG 4· K+ hydrogel that self-destructs. Chemical Communications, 
2016. 52(28): p. 5037-5040. 
23. Branco, M.C., et al., Macromolecular diffusion and release from self-assembled β-hairpin 
peptide hydrogels. Biomaterials, 2009. 30(7): p. 1339-1347. 
24. Branco, M.C., et al., The effect of protein structure on their controlled release from an 
injectable peptide hydrogel. Biomaterials, 2010. 31(36): p. 9527-9534. 
25. Koutsopoulos, S., et al., Controlled release of functional proteins through designer self-
assembling peptide nanofiber hydrogel scaffold. Proceedings of the National Academy of 
Sciences of the United States of America, 2009. 106(12): p. 4623-4628. 
26. Johnson, L., et al., Low Molecular Weight Nucleoside Gelators: A Platform for Protein 
Aggregation Inhibition. Molecular Pharmaceutics, 2019. 16(1): p. 462-467. 
27. Conejero-Muriel, M., et al., Influence of the chirality of short peptide supramolecular 
hydrogels in protein crystallogenesis. Chemical Communications, 2015. 51(18): p. 3862-3865. 
28. Kiyonaka, S., et al., Semi-wet peptide/protein array using supramolecular hydrogel. Nature 
Materials, 2003. 3: p. 58. 
29. Scott, G., et al., Pickering Stabilized Peptide Gel Particles as Tunable Microenvironments for 
Biocatalysis. Langmuir, 2013. 29(46): p. 14321-14327. 
30. Barichello, J.M., et al., Absorption of insulin from Pluronic F-127 gels following subcutaneous 
administration in rats. International Journal of Pharmaceutics, 1999. 184(2): p. 189-198. 
31. Wang, P.L. and T.P. Johnston, Sustained-release interleukin-2 following intramuscular 
injection in rats. International Journal of Pharmaceutics, 1995. 113(1): p. 73-81. 
32. Skilling, K.J., et al., Developing a self-healing supramolecular nucleoside hydrogel. Soft 
Matter, 2016. 12(43): p. 8950-8957. 
Jo
u n
l P
e-p
ro
f
24 
 
33. Angelerou, M., et al., A supramolecular nucleoside-based gel: Molecular dynamics simulation 
and characterization of its nanoarchitecture and self-assembly mechanism. Langmuir, 2018: 
p. 6912-6920 
 
34. Udenfriend, S., et al., Fluorescamine: A Reagent for Assay of Amino Acids, Peptides, Proteins, 
and Primary Amines in the Picomole Range. Science, 1972. 178(4063): p. 871-872. 
35. Royer, C.A., Probing Protein Folding and Conformational Transitions with Fluorescence. 
Chemical Reviews, 2006. 106(5): p. 1769-1784. 
36. Guilbaud, J.-B. and A. Saiani, Using small angle scattering (SAS) to structurally characterise 
peptide and protein self-assembled materials. Chemical Society Reviews, 2011. 40(3): p. 
1200-1210. 
37. Angelerou, M.G.F., et al., Hydrophobicity of surface-immobilised molecules influences 
architectures formed via interfacial self-assembly of nucleoside-based gelators. Soft Matter, 
2018. 14(48): p. 9851-9855. 
38. Soukasene, S., et al., Antitumor Activity of Peptide Amphiphile Nanofiber-Encapsulated 
Camptothecin. ACS Nano, 2011. 5(11): p. 9113-9121. 
39. Gráf, L., L. Szilágyi, and I. Venekei, Chymotrypsin, in Handbook of Proteolytic Enzymes (Third 
Edition). 2013, Elsevier. p. 2626-2633. 
40. Smith, M.E. and D.G. Morton, The Digestive System: Systems of the Body Series. 2011: 
Elsevier Health Sciences. 
41. Kruger, N.J., The Bradford method for protein quantitation, in The protein protocols 
handbook. 2002, Springer. p. 15-21. 
42. Berg, J., et al., Biochemistry, Ed 5th. 2002, WH Freeman, New York. 
43. Shugar, D., The measurement of lysozyme activity and the ultra-violet inactivation of 
lysozyme. Biochimica et biophysica acta, 1952. 8(C): p. 302-309. 
44. Dooley, K.A., S. Millinder, and T.F. Osborne, Sterol regulation of 3-hydroxy-3-methylglutaryl-
coenzyme A synthase gene through a direct interaction between sterol regulatory element 
binding protein and the trimeric CCAAT-binding factor/nuclear factor Y. Journal of Biological 
Chemistry, 1998. 273(3): p. 1349-1356. 
45. Smith, J.R., et al., Multiple sterol regulatory elements in promoter for hamster 3-hydroxy-3-
methylglutaryl-coenzyme A synthase. Journal of Biological Chemistry, 1988. 263(34): p. 
18480-18487. 
46. Harris, I.R., et al., Regulation of HMG-CoA synthase and HMG-CoA reductase by insulin and 
epidermal growth factor in HaCaT keratinocytes. Journal of investigative dermatology, 2000. 
114(1): p. 83-87. 
47. Mayo Clinic Laboratory. Serum Insulin range of values for normal population at fasting. . 
Available from: https://www.mayomedicallaboratories.com/test-
catalog/Clinical+and+Interpretive/62990. 
48. Melmed, S., et al., Williams Textbook of Endocrinology. Philadelphia, PA: Saunders Elsevier, 
2011. 
49. Rees, A.R. and M.J. Sternberg, From Cells to Atoms: An illustrated introduction to molecular 
biology. 1984. 
50. Bravo, S.B., et al., Humanized medium (h7H) allows long-term primary follicular thyroid 
cultures from human normal thyroid, benign neoplasm, and cancer. The Journal of Clinical 
Endocrinology & Metabolism, 2013. 98(6): p. 2431-2441. 
51. Son, A.R., et al., Direct chemotherapeutic dual drug delivery through intra-articular injection 
for synergistic enhancement of rheumatoid arthritis treatment. Scientific reports, 2015. 5: p. 
14713. 
52. Anderson, J.M. and M.S. Shive, Biodegradation and biocompatibility of PLA and PLGA 
microspheres. Advanced drug delivery reviews, 1997. 28(1): p. 5-24. 
Jo
urn
al 
Pre
-pr
oo
f
25 
 
53. Anderson, J.M., In vivo biocompatibility of implantable delivery systems and biomaterials. 
European journal of pharmaceutics and biopharmaceutics, 1994. 40(1): p. 1-8. 
54. Motulsky, A., et al., Characterization and biocompatibility of organogels based on L-alanine 
for parenteral drug delivery implants. Biomaterials, 2005. 26(31): p. 6242-6253. 
55. Anderson, J.M., Biological responses to materials. Annual review of materials research, 2001. 
31(1): p. 81-110. 
56. Garcia-Rendueles, A., et al., Rewiring of the apoptotic TGF-β-SMAD/NFκB pathway through 
an oncogenic function of p27 in human papillary thyroid cancer. Oncogene, 2017. 36(5): p. 
652. 
 
 
Jo
urn
al 
Pre
-pr
oo
f
